FemTherapeutics is a medical device company developing “Invisalign for Gynaecology”. Leveraging artificial intelligence and 3D Printing, our gynaecology platform offers patient-specific intra-vaginal devices for common pelvic health conditions. Our first product is a custom pessary for the management of Pelvic Organ Prolapse and Stress Urinary Incontinence, which affects 50% of women during their lifetime. FemTherapeutics is building the infrastructure to allow expansion into other pelvic health categories including menstruation and sexual wellness, labor and delivery, oncology, and more. 

Ministère de l'Économie et de l'Innovation

Centech

Fonds de solidarité FTQ

Natural Sciences and Engineering Research Council of Canada (NSERC)

McGill University

Mitacs

Montréal inc.

Mouvement des accelerateurs d'innovation du Quebec

National Research Council Canada

Investissement Quebec

SheBoot

The 51 Ventures

2048 Ventures

FemTherapeutics Inc.

Myovant Sciences is a biopharmaceutical company focused on developing innovative treatments for uterine fibroids and endometriosis. They are known for their drug, Relugolix-CT, which is used to treat heavy menstrual bleeding and severe pain caused by uterine fibroids and endometriosis.

Myovant Sciences

AbbVie is a pharmaceutical company that has been involved in developing drug delivery systems for the treatment of endometriosis and uterine fibroids. They have conducted studies evaluating the efficacy of using drug combinations for these conditions.

AbbVie

Boston Scientific is a medical device company that offers alternatives to hysterectomy, such as myomectomy and uterine fibroid embolization. They provide non-surgical treatment options for uterine fibroids.

Boston Scientific

FemTherapeutics is a biotechnology company focused on developing novel therapeutics for female reproductive health. The company leverages its proprietary drug delivery platform to address unmet medical needs in women's health, with an emphasis on non-hormonal treatments for conditions like uterine fibroids and endometriosis.

FemTherapeutics

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	May 14, 2024 7:42 AM	551e1124
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	bbbe49eb
crunchbase profile	general
li profile	general	May 14, 2024 7:42 AM	4ad526dc
translate crunchbase fundingrounds	general
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:FEMTHERAPEUTICS

FemTherapeutics